Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
1. A method for the treatment of microbial infections in a mammal comprising:
administering to said mammal in need of said treatment a pharmaceutical composition comprising a defensin in an amount effective for the treatment of said microbial infections, thereby treating said microbial infections, wherein said microbial infections are caused by a microbe selected from the group consisting of NTHi strain 12 , M. catarrhalis, S. pneumoniae serotype 3, and S. pneumoniae serotype 6B.
2. The method of claim 1 , wherein said microbial infections are selected from the group consisting of otitis media, paranasal sinusitis, labyrinthitis and meningitis.
3. The method of claim 1 , wherein said administering is orally, intranasally, or into the ear canal.
4. The method of claim 1 , wherein said defensin is alpha-defensin or beta-defensin.
5. The method of claim 4 , wherein said beta defensin is selected from the group consisting of beta-defensin 1, beta-defensin 2 and EP2E.
6. The method of claim 4 , wherein said beta-defensin is EP2E.
7. The method of claim 1 , wherein said pharmaceutical is administered at a dose of about 0.1 to 1000 mg/kg/day.
8. The method of claim 1 , wherein said pharmaceutical is a solution or suspension.
9. The method of claim 1 , wherein said pharmaceutical further comprises a salt chelator.
10. The method of claim 5 , wherein said pharmaceutical further comprises lysozyme.
11. The method of claim 1 , wherein said pharmaceutical composition comprises lysozyme, beta-defensin 1, beta-defensin 2, and EP2E.
12. The method of claim 1 , wherein said mammal is a human.
13. The method of claim 1 , wherein said mammal is an animal selected from the group consisting of: a dog, a cat, a horse, a ferret, a mouse, a rat and a cow.
14. A method for the treatment of microbial infections in a mammal comprising
administering to said mammal in need of said treatment a pharmaceutical composition comprising EP2E in an amount effective for the treatment of said microbial infections, thereby treating said microbial infections, wherein said microbial infections are caused by NTHi strain 12 , M. catarrhalis, S. Pneumoniae serotype 3, and S. pneumoniae serotype 6B.
15. The method of claim 14 , wherein said microbial infections are selected from the group consisting of otitis media, paranasal sinusitis, labyrinthitis and meningitis.